Liquidia Corporation Common Stock (LQDA) Stock Price
LQDAStock
$67.69+146.50%52W
Market Cap$6.06B
P/E—
PEG Ratio—
Div yield—
Beta0.53
LQDA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)89.71%
Price vs S&P 500 (4W)-20.81%
VGM Score60.90
LQDA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.84 | $0.74 | -11.48%(-$0.10) | |
| Q1 2026 | $0.41 | $0.52 | +28.08%(+$0.11) | |
| Q4 2025 | $0.33 | $0.15 | -55.09%(-$0.18) | |
| Q3 2025 | -$0.40 | -$0.04 | +90.03%(+$0.36) | |
| Q2 2025 | -$0.39 | -$0.49 | -24.84%(-$0.10) |
LQDA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.36
4.21
4.13
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LQDALiquidia Corporation Common Stock | F | A | B | $67.69 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Liquidia Corporation Common Stock
Liquidia Corp is a biopharmaceutical company focused on pulmonary hypertension and related lung diseases. The company leverages proprietary PRINT technology to engineer uniform drug particles, enabling its lead product YUTREPIA (treprostinil) inhalation powder, while also generating revenue from Treprostinil Injection sales.